BiochemProbe — Life Science Research Reagents

Ulixertinib hydrochloride salt form · hydrochloride · Parent Ulixertinib hydrochloride · Synonyms: BVD-523 hydrochloride

Ulixertinib hydrochloride is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases.

For research use only. Not for human or veterinary use.

Target ERK
Research area Cancer
Purity >98% Stock Inquire
Data Sheet SDS COA

Ulixertinib hydrochloride structure

CAS No.: 1956366-10-1

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
500 mg USD 685.00 BP-02521A-500mg In stock Get quote
1 g USD 985.00 BP-02521A-1g Inquire Get quote
2 g USD 1,650.00 BP-02521A-2g In stock Get quote
5 g USD 2,850.00 BP-02521A-5g In stock Get quote
10 g Inquire BP-02521A-10g In stock Inquire
Custom Size Bulk Inquiry

Description

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

Biological activity

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

Identifiers

SMILES
O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO.[H]Cl
InChIKey
DKGYQCPFBWFTHM-FSRHSHDFSA-N

Specifications

MW (average)
469.7920
Formula
C21H23Cl3N4O2
CAS No.
1956366-10-1
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO,H2O

In vitro
DMSO : 100 mg/mL H2O : < 0.1 mg/mL

Documents

References

[1].Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.
[2].Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801.

Same target

Search ERK

Same research area

Search Cancer